<DOC>
	<DOCNO>NCT03059693</DOCNO>
	<brief_summary>Atopic dermatitis ( AD ) chronic inflammatory skin disease characterize disturbance epidermal-barrier function result intensely pruritic subacute chronic eczematous plaque . As common cause chronic inflammatory skin disease , AD major cause morbidity suffering , affect upto 30 % child , increase prevalence throughout world . It estimate direct cost AD US alone range $ 0.9 billion $ 3.8 billion every year . The current therapy AD reactive , flare treat symptomatic management topical corticosteroid calcineurin inhibitor . Given medication long-term side-effects , give chronically relapse immunopathogenic nature AD , imperative need safer anti-inflammatory medication . Haus Bioceuticals ( Haus ) develop topical treatment eczema/atopic dermatitis ( AD ) denote HAT1 , demonstrate HAT1 safe profoundly effective treatment AD , control sign symptom 85 % patient AD . This study aim evaluate potential develop HAT1 integral part AD therapy .</brief_summary>
	<brief_title>Efficacy Tolerability HAT1 Patients With Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description>This study 17 week ( 119 day ) randomize , double-blind , home use study among 48 male female subject moderate severe active atopic dermatitis ( AD ) . The study include subject age 12 - 65 year old inclusive . Group assignments balanced disease severity , age , body location AD lesion ( list order importance ) . The study consist 1 week washout period , 12 week treatment phase 4 week regression phase . During treatment phase , subject provide one two test product use twice daily lesion non-lesional area instruct . No additional cream , lotion soap provide test product allow throughout duration study . Measurements , expert visual assessment self-assessments take described . Safety tolerability evaluate incidence AE 's ( define per CTCAE ) , exacerbation , application site reactions/infections , lab evals . There also consumption/compliance check dermatological evaluation visit .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Moderate severe atopic dermatitis determine Physician 's Global Assessment ( PGA &gt; 3 ) Males female , age 12 65 year old inclusive Is currently participate participate another interventional clinical study facility past 2 week . Currently diagnose treat cancer past 5 year . Requires topical systemic medication could affect course atopic dermatitis study period ( except inhale steroid and/or stable antihistamine asthma allergy ) . Has know hypersensitivity corticosteroid cream . Has active infection use antibiotic past 7 day . Has physical attribute skin condition might interfere clear visual instrumental assessments. ( i.e . cut , sunburn , birth mark , tattoo , extensive scarring , excessive hair growth acne ) Has immunologic infectious disease ( e.g . hepatitis , tuberculosis , HIV AIDS , lupus rheumatoid arthritis ) could place subject risk interfere accuracy study result . Has use immunosuppressant drug immunotherapy within past 30 day 5 halflives . Is employee sponsor company clinical test site . Is dependent oral medication skin disease/condition could , opinion Investigator tolerate restriction discontinue medicine require study . Is currently pregnant lactate plan become pregnant next 6 month ( use double contraception prevention ) . Has history keloid formation follow skin injury . Is routinely take anticoagulant medication ( i.e . Plavix , Coumadin , warfarin , heparin , etc . ) Any condition factor Investigator duly assign representative believe may affect ability subject complete study interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Eczema</keyword>
	<keyword>Topical</keyword>
</DOC>